Program Official

Principal Investigator

Daniel W.
Lin
Awardee Organization

Fred Hutchinson Cancer Center
United States

Fiscal Year
2023
Activity Code
U01
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

Prostate cancer Active Surveillance Study (PASS) Cohort: Infrastructure Support for Cancer Research

We propose to support the established Prostate cancer Active Surveillance Study (PASS) cohort, which is a large multi-institutional cohort of men with clinically localized prostate cancer who have elected active surveillance to manage their cancer. With broad eligibility criteria designed to represent the population of men who utilize active surveillance, the cohort has over 2,100 participants with extensive clinical and epidemiological data (demographic, lifestyle, quality of life, long-term outcomes) and longitudinal biospecimens (germline DNA, serum, plasma, urine, and prostate tissue) collected according to a standardized protocol. The cohort was established in 2008 in response to the growing evidence of prostate cancer overtreatment and the need for a prospective study to discover and validate biomarkers of prostate cancer progression, and to identify determinants of cancer progression and patient outcomes. Over the past decade, the cohort has amassed a wealth of data and biospecimens so that it serves as the foundation for addressing critical questions relevant to the optimal personalized management of early stage prostate cancer. The successful funding of this application will support a robust infrastructure for PASS that in turn will ensure the availability of PASS data and specimens to facilitate research addressing determinants of cancer progression, recurrence, and outcomes. A substantial proportion of these research endeavors are encompassed in currently funded federal grants, and the successful completion of the current and future projects relies on the continued success of the PASS enterprise. The impact of this cohort lies in its potential to investigate research questions of paramount importance: to identify better prognostic markers of prostate cancer aggressiveness; to understand the clinical management, progression and outcomes of early stage prostate cancer; to tailor the approach of active surveillance based on individual characteristics and preferences; to characterize associations between clinicopathologic factors, patient lifestyle, and disease biology; to develop new tools to communicate medical information to patients; and to understand decisionmaking among patients on active surveillance, in particular with regards to quality of life, anxiety, and regret . The successful completion of these transformative research endeavors will address unmet needs in the most commonly diagnosed male cancer and substantially reduce the current public health burden of early stage prostate cancer.

Publications

  • Schenk JM, Liu M, Neuhouser ML, Newcomb LF, Zheng Y, Zhu K, Brooks JD, Carroll PR, Dash A, Ellis WJ, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Wagner AA, Lin DW. Dietary Patterns and Risk of Gleason Grade Progression among Men on Active Surveillance for Prostate Cancer: Results from the Canary Prostate Active Surveillance Study. Nutrition and cancer. 2023;75(2):618-626. Epub 2022 Nov 7. PMID: 36343223
  • Brady L, Newcomb LF, Zhu K, Zheng Y, Boyer H, Sarkar N, McKenney JK, Brooks JD, Carroll PR, Dash A, Ellis WJ, Filson CP, Gleave ME, Liss MA, Martin F, Morgan TM, Thompson IM, Wagner AA, Pritchard CC, Lin DW, Nelson PS. Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance. Cancer medicine. 2022 Nov;11(22):4332-4340. Epub 2022 Apr 25. PMID: 35467778
  • Lin DW, Zheng Y, McKenney JK, Brown MD, Lu R, Crager M, Boyer H, Tretiakova M, Brooks JD, Dash A, Fabrizio MD, Gleave ME, Kolb S, Liss M, Morgan TM, Thompson IM, Wagner AA, Tsiatis A, Pingitore A, Nelson PS, Newcomb LF. 17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 May 10;38(14):1549-1557. Epub 2020 Mar 4. PMID: 32130059
  • Cooperberg MR, Zheng Y, Faino AV, Newcomb LF, Zhu K, Cowan JE, Brooks JD, Dash A, Gleave ME, Martin F, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Carroll PR, Lin DW. Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. JAMA oncology. 2020 Oct 1;6(10):e203187. Epub 2020 Oct 8. PMID: 32852532
  • Kirk PS, Zhu K, Zheng Y, Newcomb LF, Schenk JM, Brooks JD, Carroll PR, Dash A, Ellis WJ, Filson CP, Gleave ME, Liss M, Martin F, McKenney JK, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Gore JL. Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. Cancer. 2022 Jan 15;128(2):269-274. Epub 2021 Sep 13. PMID: 34516660
  • Filson CP, Zhu K, Huang Y, Zheng Y, Newcomb LF, Williams S, Brooks JD, Carroll PR, Dash A, Ellis WJ, Gleave ME, Liss MA, Martin F, McKenney JK, Morgan TM, Wagner AA, Sokoll LJ, Sanda MG, Chan DW, Lin DW. Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance. The Journal of urology. 2022 Nov;208(5):1037-1045. Epub 2022 Jul 5. PMID: 35830553
  • Schenk JM, Newcomb LF, Zheng Y, Faino AV, Zhu K, Nyame YA, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW. African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study. The Journal of urology. 2020 Apr;203(4):727-733. Epub 2019 Oct 25. PMID: 31651227
  • Jiang Y, Meyers TJ, Emeka AA, Cooley LF, Cooper PR, Lancki N, Helenowski I, Kachuri L, Lin DW, Stanford JL, Newcomb LF, Kolb S, Finelli A, Fleshner NE, Komisarenko M, Eastham JA, Ehdaie B, Benfante N, Logothetis CJ, Gregg JR, Perez CA, Garza S, Kim J, Marks LS, Delfin M, Barsa D, Vesprini D, Klotz LH, Loblaw A, Mamedov A, Goldenberg SL, Higano CS, Spillane M, Wu E, Carter HB, Pavlovich CP, Mamawala M, Landis T, Carroll PR, Chan JM, Cooperberg MR, Cowan JE, Morgan TM, Siddiqui J, Martin R, Klein EA, Brittain K, Gotwald P, Barocas DA, Dallmer JR, Gordetsky JB, Steele P, Kundu SD, Stockdale J, Roobol MJ, Venderbos LDF, Sanda MG, Arnold R, Patil D, Evans CP, Dall'Era MA, Vij A, Costello AJ, Chow K, Corcoran NM, Rais-Bahrami S, Phares C, Scherr DS, Flynn T, Karnes RJ, Koch M, Dhondt CR, Nelson JB, McBride D, Cookson MS, Stratton KL, Farriester S, Hemken E, Stadler WM, Pera T, Banionyte D, Bianco FJ Jr, Lopez IH, Loeb S, Taneja SS, Byrne N, Amling CL, Martinez A, Boileau L, Gaylis FD, Petkewicz J, Kirwen N, Helfand BT, Xu J, Scholtens DM, Catalona WJ, Witte JS. Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment. HGG advances. 2022 Jan 13;3. (1). Epub 2021 Nov 19. PMID: 34993496
  • Waisman Malaret AJ, Chang P, Zhu K, Zheng Y, Newcomb LF, Liu M, McKenney JK, Brooks JD, Carroll P, Dash A, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Nelson PS, Lin DW, Wagner AA. Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort. The Journal of urology. 2022 Apr;207(4):805-813. Epub 2021 Dec 2. PMID: 34854745
  • Liss MA, Newcomb LF, Zheng Y, Garcia MP, Filson CP, Boyer H, Brooks JD, Carroll PR, Cooperberg MR, Ellis WJ, Gleave ME, Martin FM, Morgan T, Nelson PS, Wagner AA, Thompson IM Jr, Lin DW. Magnetic Resonance Imaging for the Detection of High Grade Cancer in the Canary Prostate Active Surveillance Study. The Journal of urology. 2020 Oct;204(4):701-706. Epub 2020 Apr 28. PMID: 32343189
  • Cooley LF, Emeka AA, Meyers TJ, Cooper PR, Lin DW, Finelli A, Eastham JA, Logothetis CJ, Marks LS, Vesprini D, Goldenberg SL, Higano CS, Pavlovich CP, Chan JM, Morgan TM, Klein EA, Barocas DA, Loeb S, Helfand BT, Scholtens DM, Witte JS, Catalona WJ, Collaborators, Klotz LH, Carter HB, Carroll PR, Fleshner NE, Roobol MJ, Sanda MG, Evans CP, Dall'Era MA, Stanford JL, Newcomb LF, Higano CS, Loeb S, Karnes RJ, Gaylis FD, Kundu SD, Koch M, Nelson JB, Cookson MS, Scherr DS, Bianco FJ Jr, Amling CL, Costello AJ, Chow K, Taneja SS, Corcoran NM, Cooperberg MR, Gregg JR, Loblaw A, Stadler WM, Ehdaie B, Jiang Y, Stratton KL, Rais-Bahrami S, Dallmer JR, Gordetsky JB, Kim J, Xu J, Flynn T, Delfin M, Mamawala M, Lopez IH, Cowan JE, Venderbos LD, Arnold R, Patil D, Siddiqui J, Helenowski I, Lancki N, Kolb S, Komisarenko M, Benfante N, Perez CA, Garz S, Barsa D, Mamodev A, Petkewicz J, Kirwen N, Arsovska O, Wu E, Landis T, Martin R, Brittain K, Gotwald P, Steele P, Stockdale J, Vij A, Phares C, Dhondt CR, McBride D, Farriester S, Hemken E, Pera T, Banionyte D, Byrne N, Martinez A, Boileau L, The Prostate Cancer Foundation in Rotterdam, The Canary Prostate Active Surveillance Study (PASS). Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort. The Journal of urology. 2021 Nov;206(5):1147-1156. Epub 2021 Sep 10. PMID: 34503355